

---

## Kala Pharmaceuticals Announces Closing of \$68 Million Series C Financing

APRIL 15, 2016

On April 13, 2016, Kala Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, announced that it closed a \$68 million Series C preferred stock financing.

The WilmerHale team representing Kala in this deal included [Lia Der Marderosian](#), [Mick Bain](#) and Leora Rodenstein.

[Read Kala's press release.](#)